News

Mona Shahriari, MD, and Andrew F Alexis, MD, MPH, discussed the multifaceted considerations dermatologists should weigh when treating patients with skin of color diagnosed with plaque psoriasis.

24-month results from OAKS and DERBY show that pegcetacoplan significantly reduced GA lesion growth with both monthly and every-other-month dosing.

These findings, presented at the Fall Clinical Dermatology conference, resulted from the ADjoin long-term extension study.

The approval was announced by Zydus Life Sciences Limited in a press release on October 20, 2023.

Exposure to maternal diabetes during pregnancy is associated with an increased risk of depression and anxiety in offspring later in life, according to a new study.

This interview at the Fall Clinical Dermatology conference featured a discussion with Dr. Bhatia regarding key insights from his talk ‘What You Need To Know NOW About Actinic Keratosis.’

A convolutional neural network accurately predicted eyes that progressed from intermediate AMD to GA within 1 year using volumetric SD-OCT scans.

Susan C. Taylor, MD, emphasizes the importance of understanding the unique biological differences and needs of individuals with skin of color.

In this interview on the conference floor at Fall Clinical Dermatology, Dr. Lio discussed the important topic of treating patients with eczema that have skin of color.

This presentation at the Fall Clinical Dermatology conference in Las Vegas explored the topic of advancements in HS treatment.

Benjamin Lockshin, MD, explains the current landscape of oral medications for plaque psoriasis, emerging developments in treatment, and the importance of shared decision-making.

Although both anti-VEGFs maintain a consistent safety profile, aflibercept shows a more pronounced short-term inhibitory effect on inflammation after vitrectomy for diabetic retinopathy.

Final data from STARS Nutrition were presented at United European Gastroenterology Week 2023, demonstrating a significant reduction in parenteral support.

This case report from Brady Pregerson, MD, features a woman in her mid-80s with a history of ASCVD admitted for intermittent chest pain. Check out the ECG and determine the correct diagnosis!

New cross-sectional research indicates factors influencing ocular lesion status can include diabetes status, prednisolone dosage, and systemic infection status after kidney transplantation.

An analysis of more 13,000 children with type 1 diabetes suggests puberty onset in children with type 1 diabetes is occurring earlier now than it had been at the turn of the century.

Results from the phase 3 NEAR-1 and NEAR-2 clinical trials show consistent efficacy and tolerability of the preservative-free, low-dose eye drop in patients with presbyopia.

Results from the phase 3 ATLANTIS study showed amitriptyline was superior to placebo across multiple symptom-based outcomes for patients with IBS.

The approval for the IL-17A and IL-17F inhibitor is supported by data showing about 80% of patients achieved nearly clear skin within 4 doses.

In the PROTECT trial, teplizumab preserved β-cell function in newly diagnosed type 1 diabetes patients, slowing the decline of C-peptide levels, but key secondary endpoints, such as time in range and HbA1c, showed numerical trends without statistical significance.

On October 17, 2023, Ardelyx Inc announced the FDA approval of tenapanor (Xphozah) for reducing serum phosphorus in adults with chronic kidney disease on dialysis as add-on therapy.

Though primarily observational, this research’s biggest asset is its experimental design and its exploration of viral stimulus-induced bronchial epithelial cell responses from asthmatic donors being treated with tezepelumab.

A recent nationwide cohort study identified statistically significant associations between IBD and DED, as well as increased risks of corneal surface damage.

An analysis of 14 studies revealed that uveitis had an estimated prevalence of 3.27% in Crohn's disease and 1.60% in ulcerative colitis.

This newly-developed prediction model evaluating CAP risk was noted as having demonstrated accuracy, strong discriminatory qualities, and practicability in clinical settings.

Results showed autologous FMT was safe and well-tolerated but did not affect time to normalized intestinal habits compared to placebo.

Findings from a systematic review and meta-analysis revealed the pooled incidence rate of cerebrovascular accidents in patients with IBD was greater than in the general population.

Despite access to care and health insurance, Hispanic and non-Hispanic Black individuals with diabetes experience poorer glycemic control compared to non-Hispanic White counterparts, revealing persistent racial disparities in healthcare.